OncoMatch/Clinical Trials/NCT05815082
ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer
Is NCT05815082 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies FOLFOX chemotherapy regimen for colorectal cancer.
Treatment: FOLFOX chemotherapy regimen — The goal of this clinical trial is to compare in resectable colorectal cancer liver metastasis patients.The main question it aims to answer is whether the 3-year progression-free survival rate (PFS) of "watching and waiting" is non-inferior to adjuvant chemotherapy in postoperative ctDNA-negative resectable colorectal cancer liver metastasis patients.Participants will undergo ctDNA testing after resection of colorectal cancer liver metastasis, and will be randomly assigned to receive adjuvant chemotherapy or "watching and waiting" treatment strategy. The researchers will compare the outcomes between the two groups to see if the PFS between the two groups is similar.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: neoadjuvant chemotherapy — neoadjuvant
have received neoadjuvant chemotherapy
Cannot have received: tumor-related investigational drug therapy
Patients who have received other tumor-related investigational drug therapy
Lab requirements
Kidney function
No severe kidney dysfunction
Liver function
No severe liver dysfunction
Cardiac function
No severe heart dysfunction
Patients with severe liver, kidney, heart and lung dysfunction, coagulation dysfunction, or serious underlying diseases who cannot tolerate chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify